Function, information, and contributions: An evaluation of national multidisciplinary team meetings for rare cancers

Linn Rosell1,2, Jessica Wihl1,3, Oskar Hagberg1, Björn Ohlsson1 and Mef Nilbert2,4,5

Abstract

National virtual multidisciplinary team meetings have been established in Swedish cancer care in response to centralized treatment of rare cancers. Though national meetings grant access to a large multidisciplinary network, we hypothesized that video-based meetings may challenge participants’ contributions to the case discussions. We investigated participants’ views and used observational tools to assess contributions from various health professionals during the multidisciplinary team meetings. Data on participants’ views were collected using an electronic survey distributed to participants in six national multidisciplinary team meetings for rare cancers. Data from observations were obtained from the multidisciplinary team meetings for penile cancer, anal cancer, and vulvar cancer using the standardized observational tools Meeting Observational Tool and Metric of Decision-Making that assess multidisciplinary team meeting functionality and participants’ contributions to the case discussions. Participants overall rated the multidisciplinary team meetings favorably with high scores for development of individual competence and team competence. Lower scores applied to multidisciplinary team meeting technology, principles for communicating treatment recommendations, and guidelines for evaluating the meetings. Observational assessment resulted in high scores for case histories, leadership, and teamwork, whereas patient-centered care and involvement of care professionals received low scores. National virtual multidisciplinary team meetings are feasible and receive positive ratings by the participants. Case discussions cover medical perspectives well, whereas patient-centered aspects achieve less attention. Based on these findings, we discuss factors to consider to further improve treatment recommendations from national multidisciplinary team meetings.

Keywords

Tumor board, multidisciplinary team conference, patient perspectives, cross-sectional study, healthcare survey

Date received: 3 December 2018; accepted: 12 March 2019

Corresponding author:

Mef Nilbert, Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Scheelev. 2, 223 62 Lund, Sweden.
Email: mef.nilbert@med.lu.se
Introduction

Case discussions in multidisciplinary team meetings (MDTMs) represent a focal point of the patient trajectory. Based on all relevant information available, a multidisciplinary and multiprofessional team of experts consider treatment alternatives and provide treatment recommendations based on the best evidence available. MDTMs have been found to be particularly relevant and beneficial in complex cases, where multidisciplinary case discussions have been reported to alter the treatment recommendation in up to one-third of the cases.1–3 Benefits linked to MDTMs include better coordination of care, development of clinical skills, and adherence to evidence-based treatment recommendations.4–8 Rare cancers are, as a group, associated with multiple challenges including late and incorrect diagnosis, adverse outcomes, limited clinical expertise, weak evidence for best practice, and difficulties in collecting large series for research and in carrying out clinical trials.9

In Sweden, with a population of 10 million, surgery and select oncologic treatments for rare cancers, during recent years, been centralized to national specialist centers. This development was motivated by needs related to equal access to high-quality care, adherence to national treatment guidelines, infrastructures for research, and patient access to clinical trials. Between 2015 and 2017, treatment for penile cancer, anal cancer, vulvar cancer, gastrointestinal cancer, hepatobiliary cancer, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) underwent such centralization. As part of this process, national virtual MDTMs were developed to grant high-quality expert opinion and coordinated treatment recommendations across geographical areas, and case discussion herein were made mandatory. In 2017, a national MDTM was also initiated for childhood cancer with treatment responsibility from six regional pediatric oncology centers.

Efficient MDTM structures are influenced by a number of factors such as case selection, access to relevant information, technical equipment, participation from qualified experts, defined roles and responsibilities, leadership and teamwork, patient-centered care, and coordination of post-MDTM work.10 Despite general agreement on the characteristics of an effective MDTM, teams show considerable variability related to, for example, organization, case selection, and decision-making processes.11,12 This variability and different cultures and traditions can be expected to be particularly challenging when MDTM teams in different geographical locations are brought together as virtual teams in national networks, which is the case in the newly established MDTMs for rare cancers in Swedish healthcare. We hypothesized that video-based meetings may challenge participants’ contributions to the case discussions. We, therefore, investigated participants’ experiences from virtual national MDTMs and assessed how different health professionals contributed the discussions and to what degree various disease-related and patient-related aspects were covered in the case discussions.

Materials and methods

Study design

With a focus on national virtual MDTMs for rare cancers, this study investigates health professionals’ views using an electronic questionnaire and through observational assessment evaluates MDTM function and participants’ contributions to the case discussions.

Setting

In Sweden, treatment for several rare cancers was centralized during 2015–2017 to two to four treatment centers. The type of treatment centralized was defined for each cancer type, but, in general, involved curative surgical and/or oncological treatment. Patients with palliative needs should, as far as possible, be treated in their local or regional hospitals, but should still be discussed at the relevant national MDTM at the time of diagnosis and when otherwise relevant for treatment recommendations. Case discussions should, according to the national standards of cancer care, be performed at the time of primary diagnosis and at the time of potential recurrence. These standards also define participating health expertise, which for anal cancer include surgeon, oncologist, radiologist, nuclear therapist, coordinator, contact nurse, and, when relevant, pathologist. The MDTMs are connected through a national video-conferencing platform. Members of the national expert teams are default participants, and responsible clinicians in regional hospitals may participate for select cases for which they are responsible or have referred. The leadership rests with the responsible physicians, which for the MDTMs included surgeons or oncologists. The national MDTM is coordinated from one of the national treatment centers, with annual rotating leadership among the two to four centers responsible. Sweden does not yet have a national formally implemented system for follow-up or evaluation of MDTMs.

Participants

All national MDTM teams for rare cancers in Sweden were eligible for the study. These included MDTMs for penile cancer, anal cancer, vulvar cancer, childhood cancer, cytoreductive surgery, advanced esophageal cancer, and hepatobiliary cancer. The latter MDTMs were grouped in the analyses motivated by a high degree of overlapping participants.
Questionnaire

Participants in the national MDTMs received a link by email to an online, SurveyMonkey-based, questionnaire designed by the study group. Two reminders were sent. Data were collected between May 2017 and May 2018. The respondents were asked to rate 14 aspects of the national MDTM they participated in on a 7-point Likert-type scale (7 corresponded to fully agree and 1 to disagree). The questionnaire was distributed to 241 participants in MDTMs for penile cancer (n=33), anal cancer (n=30), vulvar cancer (n=26), childhood cancer (n=53), cytoreductive surgery (n=12), and advanced esophageal and hepatobiliary cancer (n=87). In total, 125 (52%) health professionals responded and included 45% women with 38% of the responders being above the age of 50. Among the respondents, physicians accounted for 87%, nurses for 38%, and medical secretaries for 2%. The respondents’ disciplines were surgery (56%), medicine/oncology (26%), pediatric oncology (10%), radiology (6%), and pathology (2%).

Observations

In the observational part of the study, members of the study group used observational evaluation tools. Motivated by well-established meeting structures, weekly MDTMs, and sufficient patient volumes, the MDTMs for penile cancer, anal cancer, and vulvar cancer were selected for this part of the study. The MDTM for penile cancer had participation from the two national centers, lasted a mean of 30 min, had a mean of 19 (15–22) participants, and discussed a mean of 11 (10–14) cases. The MDTM for anal cancer had four participating centers, lasted 40 min, had a mean of 21 (18–25) participants, and discussed a mean of 5 (4–6) cases. The MDTM for vulvar cancer had four participating centers, lasted 40 min, had a mean of 20 (15–25) participants, and discussed a mean of 6 (6) cases. Each MDTM was observed at three distinct occasions with participation from two study group members (M.N., B.O., J.W., and N.A. who are MDs) to a total of six observations. The responders independently rated the national MDTMs using the standardized observational tools: Meeting Observational Tool (MDT-MOT) and Metric of Decision-Making (MDT-MODe). MDT-MOT assesses overall meeting performance to support team development based on evaluation of 10 key domains including attendance, leadership and chairing, teamwork and culture, personal development and training, physical environment, technology and equipment, organization and administration, post-meeting coordination, patient-centered care, and clinical decision-making processes. These domains are evaluated using a 5-point Likert-type scale in which 5 implies optimal function and 1 implies insufficient function. MDT-MODe evaluates the MDTM based on individual assessment of each case discussion using a 5-point Likert-type scale in which 5 implies optimal function and 1 implies insufficient function. MDT-MODe is divided into two categories: availability of information (case history, patients’ view, psychosocial aspects, comorbidity, radiological, and pathological information) and participants’ (including chair, surgeons, physiotherapist, oncologists, radiologists, pathologists, nurses, and MDTM coordinators) contributions to the case discussions. Prior to scoring, the observers read relevant publications and received oral information about the tools. Data using the MDT-MOT were collected from nine MDTMs, and data using the MDT-MODe were based on 67 case discussions.

Ethics

All data were handled anonymously and are presented at group level. The study was ethically reviewed and granted permission by the regional ethics committee at Lund University (registration number: 2016/195).

Statistical analysis

Participants’ response profiles based on Likert-type scale data and overall data from the instruments MDT-MOT and MDT-MODe are presented as diverging stacked bar charts. Data from MDT-MOT and MDT-MODe were analyzed for inter-observer variability using correlation coefficient estimates. For MDT-MOT, the total meeting score from each participant was used. For MDT-MODe, inter-observer variability was estimated for each aspect based on all cases rated, followed by a total estimate of inter-observer variability for the tool as a whole. The mean score from the two observers for each aspect were evaluated and used in further analyses, which motivates use of 0.5 intervals in the stacked bar charts. Statistical analyses were performed in R version 3.2.2.

Results

Evaluation of participants’ views

The response profiles from the 125 participants in the six national Swedish MDTMs for rare cancers are presented in Figure 1. Strongly affirmative scores (5–7) related to my role at the MDTM is clear (85%), MDTM develops team competence (81%), and MDTM develops individual competence (80%). The statements that received the lowest degree of agreement (scores 1–3) were guidelines for documentation of treatment recommendations are clear (20%), technology is well-functioning (22%), and we evaluate working with the MDTM (30%).
Observational assessment

MDT-MOT is based on six observations from each diagnosis, whereas MDT-MODe is based on the total number of cases in the total number of case discussions observed, which was 68 for penile cancer, 30 for anal cancer, and 36 for vulvar cancer. The mean scores from MDT-MOT and MDT-MODe observations were used in the further analyses. Inter-observer correlations were 0.71 for MDT-MOT and of 0.86 for MDT-MODe. MDT-MOT evaluates the MDTM as a whole. High scores were obtained for clinical decision-making processes, teamworking and culture, technology and equipment, physical environment, and leadership and chairing. Low scores applied to patient-centered care, organization, administration, and post-meeting coordination (Figure 2, Supplementary Table 1).

MDT-MODe evaluates each case discussion and considers availability of information and participants’ contributions to the case discussions. Case information and case discussions by the chair, surgeons, and oncologists scored high, whereas lower scores applied to radiologists, pathologists, nurses, physiotherapists, and MDTM coordinators (Figure 3, Supplementary Table 1). Low scores applied to information on psychosocial aspects and patients’ views.

Comparison between participants’ views and observational tools

Based on questionnaire data, MDTM participants reported high scores, for example, development of team competence (81%), development of individual competence (80%), clear MDTM goals (78%), involvement in case discussions (78%), and well-functioning leadership (77%), which was in agreement with the results from the observational tools that showed favorable scores for leadership and chairing, teamwork and culture, and personal development and training (Figures 1–3). The observational tools, however, discriminated contributions from the different disciplines with high scores for participation from surgeons and oncologists and lower scores for radiologists and pathologists. Based on the MDT-MODe, contributions from nurses, physiotherapists and MDTM coordinators received low scores.

Both observational tools suggested weak consideration of patient-related aspects such as patients’ preferences, comorbidity, and psychosocial aspects, which stand in contrast to the responses from the MDTM participants with 79% providing affirmative responses to consideration of comorbidity and 71% reporting to consider patients’ perspectives. Better outcome based on observations than questionnaire data applied to functionality of technology and equipment that was rated high using observational tools, whereas affirmative scores (5–7) for technical functionality were given by 63% of the participants.

Discussion

Main findings

National virtual MDTMs for rare cancers have, during recent years, been implemented in Swedish cancer care.
Our data suggest that case information, leadership, and teamwork are overall well-functioning, whereas contributions from nurses, physiotherapists and coordinators to the case discussions and considerations of patients’ perspectives are limited (Figures 1–3). In Sweden, the medical teams responsible for establishing national MDTMs had access to updated national standards of care and a video-based communication platform, but otherwise implemented these virtual MDTMs independently and without formalized leadership training, improvement programs, or structured evaluation plans.

Several instruments have been developed to assess and improve MDTM function, but there are no generally agreed measures or principles for MDTM evaluations. Available instruments include checklists (Multidisciplinary Team Quality Improvement Checklist (MDT-QuIC)), observation tools (Multidisciplinary Team Observational Assessment Rating Scale (MDT-OARS), MDT-MODE, MDT-MOT, and a tumor leadership assessment instrument (ATLAS)), and self-assessment instruments (Team Evaluation and ASSESSment Measure (TEAM) and Multidisciplinary Team Feedback for Improving Teamworking (MDT-FIT)).6,14,16,17 Our application of MDT-MOT and MDT-MODE was motivated by the wish to use two comparable instruments with somewhat different focus, that is, on overall function of the MDTM versus evaluation of the individual case discussions. The focus on the quality of information, the contributions to the case discussions, and the overall functionality of the meetings provide a basis for future team-led improvement programs. We demonstrate high inter-observer correlation and observations that are largely in agreement between the two observational assessment tools applied (Figures 2 and 3). MDT-MOT and MDT-MODE have been applied to MDTMs for different diagnoses.18–21 Our double readings resulted in inter-observer variabilities of 0.71 for MDT-MOT and 0.86 for MDT-MODE, which fit well with the findings from Gandamihardja et al.,19 who applied the MDT-MODE to MDTM for breast cancer with reliability coefficients of 0.73–0.93.

Studies on virtual MDTMs are rare, but experiences from regional MDTMs that connect specialists and community physicians in a geographical area demonstrate general satisfaction and suggest that virtual MDTMs are feasible and valuable.4,22 Development of individual- and team competence were two of the top-rated benefits among participants in national MDTMs (Figure 1). This suggests a potential to strengthen national professional networks, increase collaboration across geographical regions, support further education, and stimulate knowledge sharing, which has been documented in regional MDTMs.4,23,24 Access to relevant information and good teamwork with representation from all core disciplines have been identified as major determinants for reaching treatment recommendations at MDTMs.15,19,20,25 We did not observe difficulties in reaching joint treatment recommendations, which may partly be explained by the large expert network available, well-functioning leadership, and relatively few cases per MDTM with a mean of 3–8 min per case discussion.

The national Swedish MDTMs are planned for rotating leadership on an annual basis. Most MDTMs are led by surgeons, but rotating leadership that involves various disciplines and professions, for example, oncologists and specialist nurses, may be relevant to consider since experiences from other MDTMs suggest that this principle may improve
teamwork and reduce potential conflicts.\textsuperscript{25,26} Formalized MDTM structures, definition of goals, and follow-up on implementation of treatment recommendations represent future focus areas.\textsuperscript{4} Initiatives such as regular performance review, self-assessment and feedback, and e-based team training have proven effective and would likely be relevant and feasible also for national geographically disparate teams.\textsuperscript{20}

Biomedical elements have, in several MDTM settings, been shown to be better covered than psychosocial aspects, information on comorbidity, and patients’ views.\textsuperscript{13,19,27-29} A patient-centered approach is considered to be an important basis for individualized treatment recommendations\textsuperscript{14,23,24,30}, and consideration of psychosocial aspects, comorbidities, and patients’ autonomy are recognized as pillars for an effective MDTM.\textsuperscript{28,31} Data based on participants’ ratings

\textbf{Figure 3.} Observational assessment data based on MDT-MODE. Stacked-bar chart showing the results from the MDTMs for anal cancer, penile cancer, and vulvar cancer. Evaluation of (a) information and (b) contribution to the discussion. The MDT-MODE tool assesses quality of presented information and participants’ contribution to the case discussion using a 5-point scale.
and data from our observations did, in this regard, differ with 71%–79% affirmative response among participants related to comorbidity and patients’ perspectives, whereas observations rated consideration of patient-related perspectives low (Figures 1–3). Jalil et al." used the MDT-MODe tool to evaluate MDTMs for various cancer types, including urological, gastrointestinal, and head and neck cancers and reported scores comparable to ours for comorbidity (mean 2.6 vs 2.1), psychosocial considerations (1.5 vs 1.4), and patient view (1.6 vs 1.3). National MDTMs gather expertise that may be geographically far from the patient, which further underscores the need to ensure development of structures to grant consideration of patient perspectives.23,31 Furthermore, focus on patients’ preferences, performance status and comorbidities has been shown to positively influence implementation of MDTM recommendations.15,27 MDT-MODe suggested low contribution to the case discussions from nurses, physiotherapists, and MDTM coordinators with scores of 1.0–1.2 (Supplementary Table 1). This observation is supported by other studies, several of which have also applied MDT-MODe.14,15,19,20,24,29 This shortcoming likely reflects the dominance of medical aspects over patient-related aspects in the case discussions. A weak focus on rehabilitation perspectives at MDTMs has been reported from the United Kingdom.15,29,31–33 Based on the National Ewing Sarcoma MDTM in the United Kingdom, Bate et al.32 have documented that patients feel that their views should inform the decision-making process and recommend initiatives such as treatment recommendations written in plain language and development of tools to improve patient involvement and enhance communication. Soukup et al.25 demonstrated that a complete patient profile and contributions to the case review by all core disciplines drive the decision-making process at MDTMs. Our

### Table 1. Guidelines for establishing and running a national virtual multidisciplinary team meeting.

| Focus area                      | Issues for consideration and planning                                                                                                                                                                                                 |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Principles for referral**     | Definition of time points in the disease trajectory for case discussions at national MDTM Establishment of guidelines for referral, for example, directly from local/regional hospital or from national expert center Definition of referral format, including structure and content of case history and ancillary data format Implementation of mechanism that allows identification of all eligible patients in participating clinics and hospitals Implementation of a MDTM coordinator role for collection and review of all available information prior to the case discussion |
| **Infrastructure and technology** | Regular meeting times and an agreed time frame Access to an interactive communication platform on which various types of documentation and information can be shared An interconnected IT system that provides an overview of the information available Access to technical support when relevant |
| **Identifying and supporting chair and participants** | Definition of required participants to grant qualified case discussions and recommendations Selection of chair Ensuring required expertise among participants Clarification of participants’ roles with particular considerations of contributions from radiology, pathology, and care personnel Defining relevant participation from ancillary expert areas such as molecular diagnostics, rehabilitation, and palliative care Adjustment of work plans to allow case preparation, meeting participation, and relevant post-meeting work for participants |
| **Running the meeting**         | Principles for identification of all participants Chaining that grants an efficient meeting structure and encourages active participation from all participants Principles and responsibilities for documentation of case discussions and recommendations Establishment of mechanism of how patients should be screened for eligibility of clinical trials Responsibilities for communicating treatment recommendation to patients Responsibilities for communicating treatment recommendation to other healthcare providers |
| **Organizational and legal aspects** | Applicable confidentiality agreements in place Legal consideration of compliance with regulations for data transfer Relevant funding and resources in place Mandate to provide treatment recommendations across healthcare providers Principles and methods to evaluate performance and improve MDTM functionality Principles for follow up of adherence to referral principles from participating hospitals and regions |

MDTM: multidisciplinary team meeting; IT: information technology.
observations suggest that the national MDTM teams should discuss and consider how to grant an optimal balance between biomedical facts and patient-related aspects. Development of standards for how patient perspectives are granted consideration would be relevant. Such a development will likely require consideration of the current meeting format and should involve care professionals who may represent patients’ perspectives at the MDTM.

Since national MDTMs are resource demanding and require significant coordination, initiatives that grant safe and easy access to relevant information, skilled participants, well-functioning teamwork, good leadership, and efficient administrative routines are crucial. The extended number of participants from various hospitals with different routines and traditions adds a level of complexity to national MDTMs. Though overall feasible, a number of issues should be considered prior to initiation of a national MDTM for best possible outcome. These include infrastructure and technology, referral principles, requirements for participants, running principles, responsibilities for communicating recommendations, and principles for governance and evaluation of national MDTMs. Based on our experiences and observations, and on current literature, we summarized issues to consider into guidelines for virtual national MDTMs in cancer care (Table 1).

**Strengths and limitations**

We aimed to obtain a comprehensive picture rather than to perform detailed evaluations of the independent MDTMs. The combination of team members’ subjective views and objective evaluation based on observational tools represent strengths and allow for identification of areas of agreement as well as disagreement between the different measures. The concordant picture obtained for most factors and areas supports identification of relevant benefits and shortcomings. We regard a Hawthorne effect as less likely since the observers were present at one participating hospital, whereas the majority of the participants participated by video from other hospitals. Limitations include a response rate of 52% for the electronic questionnaire and observations limited to three MDTM sessions for each diagnosis. Though the observers documented good inter-observer agreement between the MDT-MODE and the MDT-MOT, the tools were new to the study group, and the evaluators may still be in the learning curve. Furthermore, the tools do not allow for scoring of individual specialists and do not account for cases where, for example, histopathological input was not considered relevant. The low scores for the contribution from nurses, physiotherapists, and MDTM coordinators may not fully reflect a suboptimal involvement, for example, limited involvement from nurses could reflect clinical trajectories where cases are discussed at the MDTM prior to being seen by the responsible nurse. Due to a limited number of answers from nurses and coordinators, subgroup analysis was not possible.

**Conclusion**

National virtual MDTMs for rare cancer type have successfully been established in Swedish cancer care. Evaluation based on participants’ views and structured observational assessment identified well-functioning leadership and teamwork, but revealed weaknesses related to patient perspectives, involvement of care professionals, and MDTM evaluation principles. To make best use of the expert networks involved in national MDTMs and to provide appropriate and acceptable treatment recommendations for patients with rare cancer type, we suggest that team review and MDTM evaluation should be prioritized with a specific focus on how patient perspectives and contributions from care personnel may be strengthened.

**Acknowledgements**

The authors would like to acknowledge Nathalie Alexandersson and Annika Wendt-Wesén for help with collecting data and the Regional Cancer Center South for support in research around MDTM perspectives. Authors also thank T. Soukup for generously sharing information on and access to the observational tools used.

**Author contributions**

All authors have relevantly contributed to the manuscript and approved of the final version and its submission.

**Conflict of interest**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

The study was ethically reviewed and granted permission by the regional ethics committee at Lund University (registration number 2016/195).

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the Swedish Cancer Society, the ALF research funds, and the FOUU funds in Region Skåne.

**Supplemental material**

Supplemental material for this article is available online.

**ORCID iD**

Mef Nilbert https://orcid.org/0000-0003-2717-1937
References

1. Raine R, Wallace I, Nic a’ Bháird C, et al. Improving the effectiveness of multidisciplinary team meetings for patients with chronic diseases: a prospective observational study. Southampton: NIHR Journals Library, 2014.

2. Restivo L, Apostolidis T, Bouhnik AD, et al. Patients’ non-medical characteristics contribute to collective medical decision-making at multidisciplinary oncological team meetings. PLoS ONE 2016; 11(5): e0154969.

3. El Saghir NS, Charara RN, Kreidieh FY, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology International Survey. J Glob Oncol 2015; 1(2): 57–64.

4. Shea CM, Teal R, Haynes-Maslow L, et al. Assessing the feasibility of a virtual tumor board program: a case study. J Healthc Manag 2014; 59(3): 177–193.

5. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. J Multidiscip Healthc 2018; 11: 49–61.

6. Blazeby JM, Wilson L, Metcalfe C, et al. Analysis of clinical decision-making in multidisciplinary cancer team meetings: a prospective observational evaluation of team clinical decision-making in multidisciplinary cancer team meetings: a prospective observational study of teams in a national survey. Ann Oncol 2013; 24(9): 2669–2678.

7. Basta YL, Bolle S, Fockens P, et al. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol 2017; 24(9): 2669–2678.

8. Boyd N, Dancey JE, Gilks CB, et al. Rare cancers: a sea of opportunity. Lancet Oncol 2016; 17(2): e52–e61.

9. National Cancer Action Team. The characteristics of an effective multidisciplinary team (MDT). London: National Cancer Action Team, 2010.

10. Rosell et al. (2014). Determinants of effective multidisciplinary team meetings: a mixed methods study. Eur J Cancer Care 2018; 28(2): e12971.

11. Alexandersson N, Rosell L, Wihl J, et al. Determinants of variable resource use for multidisciplinary team meetings in cancer care. Acta Oncol 2018; 57(5): 675–680.

12. Lamb BW, Sevdalis N, Taylor C, et al. Multidisciplinary team working across different tumour types: analysis of a national survey. Ann Oncol 2012; 23(5): 1293–1300.

13. Harris J, Taylor C, Sevdalis N, et al. Development and testing of the cancer multidisciplinary team meeting observational tool (MDT-MOT). Int J Qual Health Care 2016; 28(3): 332–338.

14. Lamb BW, Wong HW, Vincent C, et al. Teamwork and team performance in multidisciplinary cancer teams: development and evaluation of an observational assessment tool. BMJ Qual Saf 2011; 20(10): 849–856.

15. Lamb BW, Taylor C, Lamb JN, et al. Facilitators and barriers to teamwork and patient centeredness in multidisciplinary cancer teams: findings of a national study. Ann Surg Oncol 2013; 20(5): 1408–1416.

16. Taylor C, Brown K, Lamb B, et al. Developing and testing TEAM (Team Evaluation and Assessment Measure), a self-assessment tool to improve cancer multidisciplinary teamwork. Ann Surg Oncol 2012; 19(13): 4019–4027.

17. Jalil R, Soukup T, Akhter W, et al. Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS). World J Urol 2018; 36(7): 1031–1038.

18. Jalil R, Akhter W, Lamb BW, et al. Validation of team performance assessment of multidisciplinary tumor boards. J Urol 2014; 192(3): 891–898.

19. Gandamihardja T, McInerney S, Soukup T, et al. Improving team working within a breast MDT: an observational approach. Eur J Surg Oncol 2014; 40(5): 604.

20. Lamb BW, Green JS, Benn J, et al. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. J Am Coll Surg 2013; 217(3): 412–420.

21. Shah S, Arora S, Atkin G, et al. Decision-making in colorectal cancer tumor board meetings: results of a prospective observational assessment. Surg Endosc 2014; 28(10): 2783–2788.

22. Marshall CL, Petersen NJ, Naik AD, et al. Implementation of a regional virtual tumor board: a prospective study evaluating feasibility and provider acceptance. Telemed J E Health 2014; 20(8): 705–711.

23. Hahlweg P, Didi S, Kriston L, et al. Process quality of decision-making in multidisciplinary cancer team meetings: a structured observational study. BMC Cancer 2017; 17(1): 772.

24. Gandamihardja TAK, Soukup T, McInerney S, et al. Benefits, barriers and opinions on multidisciplinary team meetings: a survey in Swedish cancer care. BMC Health Serv Res 2018; 18(1): 249.

25. Soukup T, Petrides KV, Lamb BW, et al. The anatomy of clinical decision-making in multidisciplinary cancer meetings: a cross-sectional observational study of teams in a natural context. Medicine 2016; 95(24): e3885.

26. McGlynn B, Johnston M and Green J. A nurse-led multidisciplinary team approach in urology-oncology: addressing the new cancer strategy. J Clin Urol 2017; 10(5): 449–456.

27. Blazey JM, Wilson L, Metcalfe C, et al. Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 2006; 17(3): 457–460.

28. Hamilton DW, Heaven B, Thomson RG, etal. Multidisciplinary team decision-making in cancer and the absent patient: a qualitative study. BMJ Open 2016; 6(7): e012559.

29. Gandamihardja TAK, Soukup T, McInerney S, et al. Analysing breast cancer multidisciplinary patient management: a prospective observational evaluation of team clinical decision-making. World J Surg 2019; 43(2): 559–566.

30. Borras JM, Albreht T, Audisio R, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer 2014; 50(3): 475–480.

31. Taylor C, Finnegan-John J and Green JS. “No decision about me without me” in the context of cancer multidisciplinary team meetings: a qualitative interview study. BMC Health Serv Res 2014; 14: 488.

32. Bate J, Wingrove J, Donkin A, et al. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care 2018; 28(2): e12971.

33. Rankin NM, Lai M, Miller D, et al. Cancer multidisciplinary team meetings in practice: results from a multi-institutional quantitative survey and implications for policy change. Asia Pac J Clin Oncol 2018; 14(1): 74–83.